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        Regulatory T (T reg) cells expressing the tran-
scription factor forkhead box P3 (FOXP3, 
human; Foxp3, mouse) play an essential role 
in controlling immune responses to autoanti-
gens, allergens, tumor antigens, transplantation 
antigens, and infectious agents (  Hori et al., 
2003  ;   Akdis, 2006  ). Foxp3 is a member of the 
forkhead/winged-helix family of transcrip-
tional regulators, and its expression in T reg 
cells is essential for their development and 
function (  Fontenot et al., 2003  ;   Williams and 
Rudensky, 2007  ). A spontaneous mutation of the 
X-linked   Foxp3   gene in   scurfy   mice causes 
an auto  immune-like disease, whereas the muta-
tion in humans leads to immunodysregula-
tion, polyendocrinopathy, enteropathy, and 
X-linked syndrome that is also a severe multi-
organ autoimmune disease with hyper-IgE 
(  Ziegler, 2006  ). 
  Although the essential role of Foxp3 in 
central and peripheral tolerance has been ex-
tensively studied, its regulation, cooperation 
with other transcription factors, and how it 
functions in inducible T reg (iT reg) cells to 
suppress various target genes is mostly not yet 
understood. It is known that Foxp3 cooperates 
with the nuclear factor of activated T cells 
(NFAT) or nuclear factor-kappa B (NF-     B) to 
regulate the transcription of diff  erent  target 
genes (  Schubert et al., 2001  ;   Bettelli et al., 
2005  ;   Wu et al., 2006  ). The Th2 cytokine IL-4 
inhibits FOXP3 expression during T cell prim-
ing. GATA3 binds to the   FOXP3   promoter 
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  Forkhead box P3 (FOXP3)  +  CD4  +  CD25  +   inducible regulatory T (iT reg) cells play an impor-
tant role in immune tolerance and homeostasis. In this study, we show that the transform-
ing growth factor-     (TGF-    ) induces the expression of the Runt-related transcription 
factors RUNX1 and RUNX3 in CD4  +   T cells. This induction seems to be a prerequisite for the 
binding of RUNX1 and RUNX3 to three putative RUNX binding sites in the   FOXP3   promoter. 
Inactivation of the gene encoding RUNX cofactor core-binding factor-     (CBF    ) in mice 
and small interfering RNA (siRNA)-mediated suppression of RUNX1 and RUNX3 in human 
T cells resulted in reduced expression of Foxp3. The in vivo conversion of naive CD4  +   T cells 
into Foxp3  +   iT reg cells was signifi  cantly decreased in adoptively transferred   Cbfb  F/F   CD4-cre   
naive T cells into   Rag2      /        mice. Both RUNX1 and RUNX3 siRNA silenced human T reg cells 
and   Cbfb  F/F   CD4-cre   mouse T reg cells showed diminished suppressive function in vitro. 
Circulating human CD4  +   CD25  high   CD127        T reg cells signifi  cantly expressed higher levels of 
RUNX3, FOXP3, and TGF-     mRNA compared with CD4  +  CD25        cells. Furthermore, FOXP3 
and RUNX3 were colocalized in human tonsil T reg cells. These data demonstrate Runx 
transcription factors as a molecular link in TGF-    –induced Foxp3 expression in iT reg cell 
differentiation and function. 
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isolated from human PBMCs, in conditions that enable the 
development of iT reg cells. Stimulation with anti-CD2/3/28 
mAbs or TGF-      alone resulted in a minimal up-regulation of 
RUNX1 and RUNX3 mRNA (  Fig. 1 A  ).   In contrast, the 
combination of both TGF-      and anti-CD2/3/28 mAbs in-
duced RUNX1 and RUNX3 mRNAs, as well as FOXP3 
mRNA, within 48 h in naive CD4  +   T cells. This result sug-
gested further experiments to investigate whether the up-
regulation of RUNX1 and RUNX3 might be a feature of iT 
reg cells during their development or even a prerequisite for 
their induction. 
  To test this hypothesis, RUNX1 and RUNX3 expres-
sion was knocked down in human naive CD4  +   T cells by 
transfection of small interfering RNAs (siRNAs;   Fig. 1 B  ). 
Defi  ciency of RUNX1 or RUNX3 resulted in markedly re-
duced TGF-     –mediated induction of FOXP3 mRNA in 
naive CD4  +   T cells compared with control cells transfected 
with scrambled siRNA. The level of FOXP3 mRNA was 
further reduced when both RUNX1 and RUNX3 were 
knocked down in naive CD4  +   T cells during their diff  erenti-
ation to iT reg cells (  Fig. 1 B  ). 
  The infl  uence of RUNX1 and RUNX3 on the develop-
ment of other T cell subsets and their specifi  c transcription 
factor expression was further investigated. Naive CD4  +   T 
cells were cultured under Th1, Th2, T reg cell, and Th17 
diff  erentiation conditions and the mRNA expression of the 
predominant transcription factor for each cell type was subse-
quently analyzed. We observed no change in GATA3 ex-
pression in Th2 cells, T-bet expression in Th1 cells, or 
RORC2 mRNA expression in Th17 cells in which RUNX1 
and RUNX3 were knocked down compared with control 
cells. On the contrary, FOXP3 mRNA was signifi  cantly de-
creased in RUNX1- and RUNX3-defi   cient T reg cells 
compared with control cells (  Fig. 1 C  ). 
  The eff  ect of RUNX silencing on the expression level of 
intracellular FOXP3 during naive CD4  +   T cell diff  erentia-
tion to iT reg was evaluated by fl  ow cytometry. FOXP3 was 
only slightly reduced after RUNX1 silencing. Transfection 
of siRNA for RUNX3 had a stronger eff  ect. The most strik-
ing FOXP3 reduction was observed when RUNX1 and 
RUNX3 were silenced together (  Fig. 1 D  ). Similar results 
were obtained in total CD4  +   T cells (  Fig. S1   and   Fig. S2  ). 
The increased impact of combined RUNX1 and RUNX3 
knockdown implies that RUNX1 and RUNX3 might have 
redundant functions in the induction of FOXP3. In addition, 
the levels of IL-4, IL-5, IL-10, IL-13, and IFN-      in control 
siRNA-transfected or RUNX1 and RUNX3 siRNA-trans-
fected CD4  +   T cells that were cultured with or without anti-
CD2/3/28 mAb and TGF-      did not show any signifi  cant 
diff  erence (  Fig. S3  ). 
  To determine whether RUNX1 and RUNX3 are also 
expressed in human T reg cells in vivo, we isolated peripheral 
blood CD4  +   CD127         CD25  high   T reg cells and compared 
them with CD4  +   CD127  +   CD25         T cells. Circulating T reg 
cells expressed signifi  cantly higher levels of RUNX3 mRNA 
compared with CD4  +  CD25         cells. As expected, IL-10, TGF-     , 
and can repress the FOXP3 trans-activation process directly in 
Th2 cells (  Mantel et al., 2007  ). It was further demonstrated that 
both Th1 and Th2 transcription factors T-bet and GATA3 op-
pose peripheral induction of Foxp3  +   T reg cells in mice through 
STAT1-, STAT4-, and STAT6-dependent pathways (  Wei 
et al., 2007  ). Although natural T reg (nT reg) cells that diff  eren-
tiate in the thymus are characterized by their stable Foxp3 ex-
pression, the generation of iT reg cells specifi  c for allergens, 
alloantigens, and autoantigens in the periphery has been associ-
ated with a transient Foxp3  +   phenotype (  Fontenot et al., 2003  ; 
  Hori et al., 2003  ). The crucial role of TGF-      in their genera-
tion has been demonstrated. 
  The RUNX gene family (Runt-related transcription factor, 
acute myeloid leukemia [AML], core-binding factor-     [CBF    ], 
and polyoma enhancer-binding protein-2      [PEBP2     ]) con-
tains three members, RUNX1 (AML1/CBFA2/PEBP2     B), 
RUNX2 (AML3/CBFA1/ PEBP2    A), and RUNX3 (AML2/
CBFA3/PEBP2     C). They are essential transcriptional regula-
tors of diff  erent developmental pathways. RUNX2 is mostly 
important for bone development and osteoblast diff  erentiation 
(  Komori et al., 1997  ). RUNX1 plays an important role in he-
matopoiesis during development, and RUNX3 has important 
functions in thymogenesis and neurogenesis (  Wang et al., 1996  ; 
  Inoue et al., 2002 ;  Levanon et al., 2002 ). RUNX1 and RUNX3 
also work together in the establishment of lineage specifi  cation 
of T lymphocytes (  Taniuchi et al., 2002  ;   Egawa et al., 2007  ). 
  RUNX1   is a frequent target for chromosomal translocations as-
sociated with leukemias (  Look, 1997  ), and   RUNX3   methyla-
tion and silencing is observed in various human epithelial 
cancers (  Blyth et al., 2005  ). 
  RUNX family members share the Runt domain, which is 
responsible for DNA binding (  Ito, 1999  ). The Runt domain-
containing protein constitutes the      -chain partner of the 
heterodimeric CBF complex. RUNX proteins heterodimerize 
with the non–DNA-binding partner, CBF     , which increases 
the affi   nity for DNA binding and stabilizes the complex by pre-
venting ubiquitin-dependent degradation (  Wang et al., 1993  ). 
The CBF complexes regulate the expression of cellular genes 
through binding to promoters or enhancer elements. The ef-
fects of the RUNX–CBF      complex regulation are clearly cell 
lineage and stage specifi  c. They include the crucial choices be-
tween cell-cycle exit and continued proliferation, as well as be-
tween cell diff  erentiation and self-renewal (  Blyth et al., 2005  ). 
  Because of the involvement of RUNX mutations in diff  er-
ent autoimmune diseases and the known interaction with TGF-
     , we investigated the impact of RUNX1 and RUNX3 on the 
expression of FOXP3 and subsequently on the development 
and function of iT reg cells. This study demonstrates that 
RUNX1 and RUNX3 induced by TGF-      are involved in the 
development and suppressive function of Foxp3  +   iT reg cells. 
  RESULTS 
  The role of RUNX1 and RUNX3 transcription factors 
in TGF-    –mediated iT reg cell generation 
  To investigate the role of RUNX transcription factors in the 
development of iT reg cells, we cultured naive CD4  +   T cells, JEM VOL. 206, November 23, 2009 
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an analysis of human tonsils, which contain high numbers of 
FOXP3  +   T reg cells (  Verhagen et al., 2006  ). Staining of tonsil 
sections for FOXP3 and RUNX3 demonstrated in vivo 
and FOXP3 mRNAs are also expressed in circulating T reg 
cells (  Fig. 2 A  ).   There was no diff  erence in RUNX1 mRNA 
expression between these two cell subsets. We also performed 
    Figure 1.     RUNX1 and RUNX3 are involved in the induction of Foxp3 in iT reg cells.   (A) RUNX1, RUNX3, and FOXP3 mRNA induction in human 
naive CD4  +   T cells after alone or combined anti-CD2/3/28 mAb and TGF-      stimulation in the presence of IL-2. Real-time PCR of human naive CD4  +   T  cells 
after 48 h of culture. Bars show the mean ± SE of three independent experiments. (B) FOXP3 mRNA induction by anti-CD2/3/28 mAb and TGF-      in  hu-
man naive CD4  +   T cells is reduced after siRNA-mediated RUNX1/3 knockdown. Real-time PCR of RNA from human naive CD4  +   T cells, transfected with 
RUNX1 and/or RUNX3 siRNA or with a control siRNA and cultured with anti-CD2/3/28, TGF-      and IL-2. Bars show the mean ± SD of three independent 
experiments. (C) FOXP3 mRNA is down-regulated in iT reg cells after siRNA-mediated knockdown of RUNX1 and RUNX3. Real-time PCR for FOXP3, T-bet, 
GATA3, and RORC2 from human naive CD4  +   T cells, transfected with RUNX1 and RUNX3 siRNA or with scrambled siRNA (control) and cultured under iT 
reg, Th1, Th2, or Th17-driving conditions for 12 d. Bars show the mean ± SD of three independent experiments. (D) FOXP3 protein induction in iT reg cells 
is reduced after siRNA-mediated RUNX1/3 knockdown. Human naive CD4  +   T cells were transfected with RUNX1 and/or RUNX3 siRNA or with a control 
siRNA and stimulated with anti-CD2/3/28 and TGF-      in the presence of IL-2. CD4 and intracellular FOXP3 analysis by fl  ow cytometry after 72 h. One of 
three independent experiments is shown. Statistical differences were verifi  ed by the paired Student’s   t   test. *, P < 0.05; **, P < 0.01.     2704 RUNX1 and RUNX3 in functional inducible T regulatory cells   | Klunker et al. 
    Figure 2.     RUNX1 and RUNX3 expression in Foxp3  +   T reg cells and in human CD4  +  , CD127            , CD25  high   cells.   (A) Real-time PCR analysis of CD4  + , 
CD127        , and CD25  high   T reg cells and CD4  + ,  CD127 +  , and CD25  neg   T cells isolated from human peripheral blood showed an increased expression of IL-10, 
TGF-     , FOXP3, and RUNX3 mRNA in CD25  +   compared with CD25         cells. Bars show the mean ± SE of three independent experiments. (B) Human tonsil 
sections were analyzed by confocal microscopy. Tissue sections were stained for FOXP3, RUNX1, RUNX3, and DAPI or isotype controls. HEK cells RUNX1-
transfected or not transfected served as additional control for RUNX1 staining. Data shown are representative from one of the three tissue samples with 
similar results. Bars, 5 μm. Statistical differences were verifi  ed by the paired Student’s   t   test. *, P < 0.05; **, P < 0.01.     JEM VOL. 206, November 23, 2009 
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luciferase construct was cotransfected with RUNX1 or RUNX3 
expression vectors (  Fig. 4 A  ).   The increase in promoter activ-
ity was greater upon cotransfection of RUNX3 compared 
with RUNX1. Luciferase expression was abrogated when the 
Runx binding sites in the   FOXP3   promoter (     511 to +176) 
luciferase construct were mutated (  Fig. 4 A  ). In these experi-
ments, the overexpression of RUNX1 and RUNX3 elimi-
nated the need of TGF-      for FOXP3 promoter activation and 
PMA/ionomycin stimulation was suffi   cient. 
  To examine the role of each of the three RUNX binding 
sites for the   FOXP3   promoter activity, we mutated each indi-
vidually or in combination. No reduction in luciferase activity 
was observed when the      53 site was mutated and only a slight 
reduction when either the      287 or      333 site was mutated 
(  Fig. 4 B  ). However, mutating the      53 site in combination 
with one of the other two sites led to a signifi  cant decrease in 
luciferase activity, with the greatest reduction observed when 
all three binding sites were mutated (  Fig. 4 B  ), suggesting that 
the identifi   ed binding sites have redundant functions and 
RUNX binding to more than one site is necessary for the full 
activation of the   FOXP3   promoter. Supporting these fi  ndings, 
the overexpression of RUNX1 in human primary CD4  +   T 
cells resulted in signifi  cantly elevated levels of FOXP3 protein 
measured by fl  ow cytometry after 48 h. This was achieved 
without any requirement for anti-CD3, anti-CD28 stimula-
tion, or the presence of TGF-     . Although there was a trend, 
the transfection of CD4  +   T cells with RUNX3 did not lead to 
statistically signifi  cant increase in FOXP3 (  Fig. S5  ). 
  Role of CBF     in the induction of Foxp3 
  CBF     , a common cofactor of all RUNX proteins, stabilizes 
and increases the binding of the runt domain to target DNA 
sequences. To target all Runx proteins that might be in-
volved in the induction of Foxp3, we used mice in which 
loxP-fl  anked   Cbfb   alleles were inactivated in T cells through 
expression of a   CD4-cre   transgene. Retinoic acid and TGF-      
synergize in the induction of Foxp3 in naive T cells (  Kang 
et al., 2007  ). To investigate whether Runx-mediated induc-
tion of Foxp3 is dependent on the expression of CBF     , naive 
CD4  +   CD8         T cells from   Cbfb  F/F   CD4-cre   and control   Cbfb  F/+   
CD4-cre   mice were stimulated with anti-CD3/28 mAbs, ret-
inoic acid, and increasing concentrations of TGF-     . After 3 d 
in culture, the cells were restimulated with PMA and iono-
mycin and analyzed for intracellular Foxp3 and IFN-      ex-
pression. TGF-      induced Foxp3 in   Cbfb  F/+   CD4-cre   cells in a 
dose dependent manner, and this was signifi  cantly reduced in 
  Cbfb  F/F   CD4-cre   cells. Retinoic acid enhanced Foxp3 expres-
sion even in 20 pg/ml of TGF-      and more than 95% of the 
CD4  +   T cells from   Cbfb  F/+   CD4-cre   mice became Foxp3  +   in 
100 and 500 pg/ml TGF-      doses. The induction of Foxp3 
was again signifi  cantly lower in   Cbfb  F/F   CD4-cre   CD4  +   T cells 
even in the presence of retinoic acid, demonstrating that de-
fi  ciency in Runx binding to DNA aff  ects the TGF-      induc-
tion of Foxp3 in T reg cells ( Fig. 5 A ).   There was no diff  erence 
in the induction of Foxp3 when endogenous IL-4 and IFN-      
were neutralized (  Fig. S6  ). 
coexpression of these two molecules in a subset of T reg 
cells, whereas there was low RUNX1 expression in all ton-
sil cells (  Fig. 2 B  ). 
  RUNX1 and RUNX3 bind to the   FOXP3   promoter 
  Transcription element search system analysis of the human 
  FOXP3   promoter predicted 3 putative RUNX binding sites 
at 333, 287, and 53 bp upstream of the transcription start site 
(TSS). All three binding sites are conserved between human, 
mouse, and rat (  Fig. S4  ). To verify the putative binding sites 
in the  FOXP3   promoter, we transiently transfected HEK293T 
cells with RUNX1 and RUNX3. After the pull-down with 
oligonucleotides containing the wild-type binding sequences, 
but not mutant sequences, RUNX binding to the   FOXP3   
promoter oligonucleotides was detected by Western blot 
(  Fig. 3 A  ).   To confi  rm these results and test the ability of 
single binding site sequences to bind either RUNX1 or 
RUNX3, we used the promoter enzyme immunoassay. Cell 
lysates were obtained from HEK293T cells that had been 
transiently transfected with RUNX1 or RUNX3 expression 
vectors. The biotinylated   FOXP3   promoter oligonucleotides 
were linked to a streptavidin-coated microtiter plate, and 
bound RUNX1 or RUNX3 was detected by using anti-
RUNX antibodies and a peroxidase-labeled secondary anti-
body. We showed binding of RUNX1 and RUNX3 to the 
mixture of all three oligonucleotides containing the binding 
sites, whereas there was no binding detectable when a com-
bination of the mutated oligonucleotides was used in the as-
say (  Fig. 3 B  ). Although there was a similar and high degree 
of binding to the      333 and      287 sites, a lower degree of 
binding was detected when the oligonucleotide containing 
the      53 site in the Foxp3 promoter was used. This eff  ect was 
observed both for binding to RUNX1 and RUNX3 (  Fig. 3 B  ). 
The binding to the two single binding sites at      333 and 
     287 was comparable to the mixture of all three oligonucle-
otides. Chromatin immunoprecipitation (ChIP) assay results 
confi  rmed the binding of RUNX1 and RUNX3 complexes 
containing CBF      to   FOXP3   promoter during the diff  erenti-
ation of naive T cells toward T reg cells. Here, naive CD4  +   
T cells were cultured with IL-2, anti-CD2/3/28 mAb, and 
TGF-      as a Foxp3-inducing stimulation. Amplifi  cation of 
PCR products from the   FOXP3   promoter region with the 
predicted RUNX binding sites showed that RUNX1, RUNX3, 
and CBF      were immunoprecipitated together with the 
  FOXP3   promoter (  Fig. 3 C  ). Negative control primer target-
ing open reading frame-free intergenic DNA, IGX1A did 
not show any signifi  cant change in site occupancy. 
  Regulation of   FOXP3   promoter activity and FOXP3 protein 
expression by RUNX1 and RUNX3 
  To investigate the eff  ect of RUNX1 and RUNX3 binding to 
the RUNX binding sites in the   FOXP3   promoter, we trans-
fected human peripheral blood CD4  +   T cells with a   FOXP3   
promoter luciferase reporter vector and RUNX1 or RUNX3 
expression vectors. An increase in luciferase activity was ob-
served only when the   FOXP3   promoter (     511 to +176) 2706 RUNX1 and RUNX3 in functional inducible T regulatory cells   | Klunker et al. 
    Figure 3.     Binding of RUNX1 and RUNX3 proteins to the predicted binding sites in the   FOXP3   promoter.   (A) Mutated and wild-type oligonucle-
otides are shown. The predicted RUNX binding sites are accentuated (boxed and in green letters) and stars mark mutations introduced into the binding 
site of the control oligonucleotides. Nuclear extracts from HEK293T cells were incubated with biotinylated oligonucleotides. The precipitated oligonucle-
otide–transcription factor complexes were separated by SDS-PAGE and identifi  ed by Western blotting with anti-RUNX1 and anti-RUNX3 antibodies. A 
mixture of all three oligonucleotides with the predicted binding sites or with the inserted mutation into the predicted sites was used. Data shown are one 
representative of three independent experiments with similar results. (B) Promoter enzyme immunoassay using wild-type and mutated oligonucleotides 
within the   FOXP3   promoter. Bars show mean ± SE of three independent experiments. (C) Chromatin immunoprecipitation assay results show binding of 
RUNX1 and RUNX3 complexes containing CBF      to the human   FOXP3   promoter in naive CD4  +   T cells that were cultured with IL-2 together with anti-
CD2/3/28 and TGF-     . There was no change in site occupancy in all immunoprecipitations when IGX1A negative control primers were used. The results are 
normalized to input and isotype control antibody. Bars show mean ± SE of three independent experiments. Statistical differences were verifi  ed by the 
paired Student’s   t   test. *, P < 0.05     JEM VOL. 206, November 23, 2009 
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generated to permit analysis of their suppressive activity. 
Purifi  ed naive CD4  +   T cells from   Cbfb  F/F   CD4-cre   and control 
  Cbfb  F/+   CD4-cre   mice (  Cd45.2  ) harboring a   Foxp3-ires-GFP 
  allele (  Bettelli et al., 2006  ) were stimulated in vitro with anti-
CD3/28 mAbs, IL-2, and TGF-     . After 3 d, Foxp3  +  -GFP  +   
cells were sorted by fl  ow cytometry and mixed with CFSE-
labeled naive CD45.1  +   CD4  +   cells at ratios of 1:4, 1:2, and 
1:1. The cells were then incubated with inactivated spleno-
cytes and stimulated with anti-CD3 mAb for four more days. 
CD45.1  +   cells were analyzed for CFSE dilution (  Fig. 6 A  ).   
  Cbfb  F/+   CD4-cre   CD4  +   T cells activated in the presence of 
TGF-      showed a clear suppression of T cell proliferation that 
became even more apparent when an increased ratio of 
FOXP3  +  /CD25         cells was used (  Fig. 6 B  ). The suppression 
was signifi  cantly reduced when cells from   Cbfb  F/F   CD4-cre   
mice were used, demonstrating that TGF-     –induced Runx 
complexes are important for the suppressive activity of Foxp3  +   
T reg cells (  Fig. 6 B  ). As a control,   Cbfb  F/+   CD4-cre   CD4  +   
T cells activated in absence of TGF-      were mixed with 
CFSE-labeled naive CD45.1  +   CD4  +   cells. No suppression could 
be observed in all control groups without TGF-      at all tested 
ratios (  Fig. 6 C  ). The decreased suppression capacity of   Cbfb  F/F   
CD4-cre   iT reg cells was unlikely to be caused by decreased 
survival or proliferation. Foxp3  +   and Foxp3         cells generated 
from both   Cbfb  F/F   CD4-cre   and control cells all displayed simi-
lar proliferation rates and cell death as measured by CFSE dilu-
tion and annexin V staining, respectively (  Fig. S7, A and B  ). 
  In addition, we tested the requirement of RUNX1 and 
RUNX3 for the development of the suppressive capacity in 
human iT reg cells. We isolated human naive CD4  +   T cells 
and transfected them with a combination of RUNX1 and 
RUNX3 siRNA, or with a scrambled control siRNA. Cells 
were cultured under T reg conditions, and then mixed with 
CFSE-labeled autologous CD4  +   T cells and stimulated with 
anti-CD3 mAb. Cells in which RUNX1 and RUNX3 were 
knocked down showed markedly lower suppressive activity 
compared with control iT reg cells at a T reg/CD4  +   T re-
sponder cell ratio of 1:20, but not when the T reg/CD4  +   T 
responder cell ratio was increased to 1:5 (  Fig. 6 D  ). These re-
sults demonstrate the important role of RUNX1 and RUNX3 
not only for the induction of FOXP3, but also for the sup-
pressive capacity of iT reg cells both in humans and in mice. 
The data suggest both quantity and quality of T reg cells are 
hampered. Reduced intrinsic suppressive capacity of iT reg 
cells was demonstrated in mice, because Foxp3-GFP  +   cells 
were FACS sorted and same numbers of iT reg cells are in-
cluded in control experiments. In the suppression experiment 
with human cells, reduced suppressive activity was caused by 
reduced FOXP3 expression in T cells by siRNA inhibition 
of RUNX1 and RUNX3. 
  DISCUSSION 
  This study demonstrates that RUNX transcription factors 1 
and 3 play an important role in the generation of FOXP3  +   iT 
reg cells by TGF-     . TGF-      mediates RUNX induction and 
FOXP3 is effi   ciently up-regulated by RUNX1 and RUNX3 
  The importance of RUNX transcription factors for the in 
vivo conversion of naive CD4  +   T cells into iT reg cells was 
examined. Control   Cbfb  F/F     or   Cbfb  F/F   CD4-cre   naive T cells, 
harboring a   Foxp3-IRES-GFP   allele were adoptively trans-
ferred into   Rag2      /        mice. 6 wk later, CD4  +   T cells in spleen, 
mesenteric lymph node, and lamina propria of the small in-
testine were analyzed for Foxp3-GFP expression (  Fig. 5 B  ). 
There was a consistently lower percentage of CD4  +   T cells 
that had developed Foxp3 expression in the mesenteric lymph 
node and lamina propria of mice transferred with   Cbfb  F/F   
CD4-cre   cells compared with control cells (  Fig. 5, B and C  ). 
These data affi   rm the signifi  cance of RUNX proteins for the 
in vivo generation of CD4  +   Foxp3  +   T cells. 
  CBF    , RUNX1, and RUNX3 are important 
for the suppressive activity of CD25  +   Foxp3  +   T reg cells 
  Even though   Cbfb  -defi  cient CD4  +   T cells had impaired in-
duction of Foxp3 after stimulation with anti-CD3/28 mAbs 
and TGF-     , suffi     cient numbers of Foxp3  +   cells could be 
    Figure 4.     Regulation of   FOXP3   promoter activity by RUNX1 and 
RUNX3.   (A) Human primary CD4  +   cells were transfected with an empty 
vector (pGL3 Basic), a vector containing the wild-type or mutated   FOXP3  
promoter region (FOXP3      511/+176) fused to the luciferase reporter gene 
together with a GFP, RUNX1, or RUNX3 expression vector. Bars show the 
mean luciferase activity ± SE measured as arbitrary light units of three 
independent experiments. (B) Human primary CD4  +   cells were transfected 
with an empty vector (pGL3 Basic), a vector containing the putative 
  FOXP3   promoter region (FOXP3      511/+176) fused to the luciferase re-
porter gene, or with a vector containing the putative   FOXP3   promoter 
region (FOXP3      511/+176) with single RUNX binding sites mutated (53, 
287, or 333) or with the combination of two or three RUNX binding sites 
mutated (53, 287, or 333) fused to the luciferase reporter gene. Bars show 
the mean luciferase activity ± SD measured as arbitrary light units of 
three independent experiments.     2708 RUNX1 and RUNX3 in functional inducible T regulatory cells   | Klunker et al. 
    Figure 5.     Diminished capacity of   Cbfb-  defi  cient   CD4-cre   mice T cells in the generation of Foxp3  +   CD4  +   T cells  . (A) FACS-purifi  ed naive CD4  +  
CD8         T cells from   Cbfb  F/F  CD4-cre   and control   Cbfb  F/+  CD4-cre   mice were activated in vitro with anti-CD3/28 mAb, 50 U/ml IL-2, ± 10 nM retinoic acid 
(RA), and increasing concentrations of TGF-     . After 3 d in culture, the cells were restimulated with PMA + ionomycin, and then analyzed for intracellular 
Foxp3 and IFN-      expression. One of fi  ve experiments is shown. (B) Naive CD4  +   T cells from   Cbfb CD4-cre   or control mice (harboring a   Foxp3-IRES-GFP  
allele) were adoptively transferred into Rag-defi  cient mice (5 × 10  6   cells per transfer). 6 wk later, TCR     + CD4 +   cells from the spleen, mesenteric lymph node 
(MLN), and lamina propria of the small intestine (LP) were analyzed for Foxp3-GFP expression. Results from one of four   Cbfb  F/F  CD4-cre   and  control 
  Cbfb  F/+  CD4-cre   mice with same fi  ndings are shown. The data from four sets of mice is shown in C. Statistical analysis was performed with Mann-Whitney 
  U   test. *, P < 0.05 between groups.     JEM VOL. 206, November 23, 2009 
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dendritic cells in the gut-associated lymphoid tissue. It inhib-
its the IL-6–driven induction of Th17 cells and facilitates the 
diff  erentiation of naive T cells to Foxp3  +   T reg cells (  Mucida 
et al., 2007  ). We observed an increased number of Foxp3  +   cells 
by retinoic acid and TGF-      compared with TGF-      treat-
ment alone in   Cbfb  F/+   CD4-cre   mice and   Cbfb  F/F   CD4-cre   mice. 
In addition, we showed a defective in vivo generation of T 
reg cells from   Cbfb-  defi  cient CD4  +   T cells in Rag2       /       mice. 
These data in mice confi  rm the human data that RUNX pro-
teins play an important role for TGF-     –dependent FOXP3 
induction, as well as in the suppressive capacity of iT reg 
cells. As an additional support for this concept, the overex-
pression of RUNX1 induced increased FOXP3 protein ex-
pression without any requirement of TGF-      and anti-CD3 
and anti-CD28 stimulation in human primary CD4  +   cells. In 
both human and mouse systems, reduced Foxp3 expression 
was associated with reduced T reg cell suppressive activity. 
  In a recent study, the role of Runx–CBF      was investi-
gated in nT reg cell development in the thymus (  Rudra et al., 
2009  ). It was reported that Foxp3 expression in nT reg cells 
is unstable in the absence of Runx–CBF      complexes.   Cbfb-
  defi  cient nT reg cells progressively lose Foxp3 upon division, 
and there is no evidence of increased death of   Cbfb-  defi  cient 
nT reg cells in that study. The experiments in   Cbfb-  defi  cient 
  CD4-cre   T cells in mice and the knockdown experiments in 
humans in this study suggest that the induction of Foxp3 ex-
pression is a major contributing factor in the in vivo conver-
sion experiment. Here, we observed that there is a twofold 
increased Foxp3  +   iT reg cell generation in vivo. This is in the 
same range with previously published studies targeting diff  er-
ent mechanisms in Foxp3 induction (  Maynard et al., 2007  ; 
  Sun et al., 2007  ). Whether the diminished capacity of   Cbfb-
  defi  cient   CD4-cre   T cells in the generation of Foxp3 may be 
caused by peripheral expansion of   Cbfb-  defi  cient non–T reg 
cells or survival problems faced by   Cbfb-  defi  cient iT reg cells 
after Foxp3 induction remains to be elucidated. 
  The involvement of RUNX proteins in autoimmune 
diseases has been previously suggested (  Alarcón-Riquelme, 
2003  ). A mutation in the RUNX1 binding site in the pro-
moter of programmed cell death 1 gene (  PDCD-1  ) has been 
implicated in systemic lupus erythematosus pathogenesis 
(  Prokunina et al., 2002  ). Polymorphisms that alter RUNX1 
binding to other genes have also been described in rheuma-
toid arthritis linkage at 5q31 in Japanese patients (  Tokuhiro 
et al., 2003  ) and in a psoriasis linkage at 17q25 (  Prokunina 
et al., 2002  ;   Helms et al., 2003  ).   RUNX3  -defi  cient mice 
spontaneously develop infl  ammatory bowel disease and hy-
perplastic gastritis-like lesions (  Brenner et al., 2004  ). These 
disease symptoms resemble those occurring after depletion of 
Foxp3-expressing T reg cells (  Sakaguchi, 2004  ). Derepres-
sion of Th2 cytokines might also account for some of the ob-
served disease symptoms, as it was shown that T-bet fi  rst 
induces Runx3 in Th1 cells and then partners with Runx3 to 
direct lineage-specifi  c gene activation. Runx3/Cbf      are both 
required for the activation of the   Ifng   gene and silencing of 
the   Il4 gene   in Th1 cells (  Djuretic et al., 2007  ;   Naoe et al., 2007  ). 
in human CD4  +   T cells. There are three putative RUNX 
binding sites in the proximal   FOXP3   promoter. One binding 
site was predicted as a binding site for RUNX2. Promoter 
enzyme immunoassay results showed that binding of RUNX1 
and RUNX3 also occurred at this site (as well as at the other 
two), which were initially identifi   ed as RUNX1 binding 
sites. This fi  nding is not surprising because RUNX proteins 
bind to promoter or enhancer elements of their target genes 
via the runt domain, which is conserved between members 
of the RUNX family. The RUNX protein that actually in-
duces the expression of FOXP3 might therefore be depen-
dent on the availability of the specifi  c RUNX family member 
at certain stages of T cell development. RUNX proteins are 
able to increase or inhibit transcriptional activity of their tar-
get genes depending on the cell type and the target gene 
(  Otto et al., 2003  ). Mutation of only one of the three binding 
sites had only a little eff  ect on the promoter activity; how-
ever, when two binding sites were mutated, the FOXP3 pro-
moter activity dropped to a greater extent. The most striking 
eff  ect was observed when all three binding sites were mu-
tated. We therefore assume that these binding sites have par-
tially redundant functions, but binding to at least two sites 
seems to be necessary for full promoter activation. 
  TGF-      promotes or inhibits the proliferation, diff  erentia-
tion, and survival of a wide array of diff  erent cells. It is also 
produced in activated T cells and it inhibits T cell prolifera-
tion (  Kehrl et al., 1986  ;   Siegel and Massagué, 2003  ). It was 
shown that TGF-      is mandatory for the maintenance of pe-
ripheral T reg cells and their expression of Foxp3 (  Marie 
et al., 2005  ;   Rubtsov and Rudensky, 2007  ). RUNX tran-
scription factors are targets of the TGF-      superfamily and 
they are involved in the TGF-      pathway. They interact di-
rectly with regulatory SMADs (  Miyazawa et al., 2002  ;   Ito 
and Miyazono, 2003  ). TGF-      can activate RUNX genes at 
the transcriptional level, and at the posttranscriptional level 
through activation or stabilization of RUNX proteins (  Jin 
et al., 2004  ). It was shown that RUNX2 regulates the ex-
pression of TGF-      type I receptor (  Ji et al., 2001  ), suggesting 
that other mechanisms for their function could be involved. 
The fusion proteins RUNX1-EVI1 and RUNX1-ETO 
block TGF-      inhibition of leukemic cell growth. RUNX3 
plays an important role in TGF-     –mediated growth control 
in epithelial cells, as loss of RUNX3 leads to decreased sensi-
tivity to TGF-      and hyperproliferation of the gastric mucosa 
(  Blyth et al., 2005  ). The present study demonstrates that 
RUNX3 expression is more dominant in circulating human 
T reg cells and tonsil T reg cells compared with RUNX1. 
This could be dependent on the stage of the cells and organ 
from which they were isolated. 
  We observed that single siRNA interference of either 
RUNX1 or RUNX3 alone shows a slight decrease in Foxp3  +   
T reg cell induction, which could be caused by redundancy 
of these proteins. For this reason, we decided to use   Cbf      F/F   
CD4-cre   mice. Foxp3 induction by TGF-      is reduced 
in CD4  +   T cells of   Cbfb  F/F   CD4-cre   mice compared with 
  Cbfb  F/+   CD4-cre   mice. Retinoic acid is secreted by a subset of 2710 RUNX1 and RUNX3 in functional inducible T regulatory cells   | Klunker et al. 
    Figure 6.       Cbfb  F/F   CD4-cre   mouse cells and iT reg cells generated from human naive CD4  +   T cells undergoing siRNA-mediated RUNX1 and 
RUNX3 knock down show a diminished suppressive activity.   Experimental  setup    (A) and results of the mouse suppression assay (B), FACS-purifi  ed JEM VOL. 206, November 23, 2009 
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  Foxp3 protein interacts not only with RUNX proteins 
but also with several other transcriptional partners, such as 
NFAT and possibly NF-     B; with histone acetyl transferases, 
such as TIP60; and histone deacetyl transferase (HDAC) 
complexes, such as HDAC7 and HDAC9 (  Wu et al., 2006  ; 
  Sakaguchi et al., 2008  ). NFAT forms a complex with AP-1 
and NF-     B and regulates the expression of IL-2, IL-4, IFN-     , 
and CTLA4 in conventional T cells, which leads to the acti-
vation and diff  erentiation to eff  ector T cells (  Dolganov et al., 
1996  ;   Hu et al., 2007  ). The NFAT–AP-1 complex also binds 
to the   Foxp3   promoter after TCR triggering and regulates its 
gene expression positively (  Mantel et al., 2006  ). It was shown 
that NFAT and Smad3 cooperate to induce   Foxp3   expression 
through its enhancer (  Tone et al., 2008  ), but no TGF-      re-
sponse element was identifi  ed in the   Foxp3   gene or in the 
surrounding regions. The initial induction of RUNX1 and 
RUNX3 and the subsequent binding of these transcription 
factors to the   Foxp3   promoter that we showed here might 
explain the relatively late induction of   Foxp3   mRNA that 
peaks 24–48 h after stimulation. The interaction of Foxp3 
and NFAT is dependent on their cooperative binding to 
DNA (  Wu et al., 2006  ). RUNX1 alone, or together with its 
interacting partners p300 and CREB-binding protein, may 
cooperate with the NFAT transcription complex to activate 
the   IL-2   promoter (  Sakaguchi et al., 2008  ). Similar to this 
interaction, NFAT may also cooperate with RUNX1 or 
RUNX3 to activate Foxp3, but further studies are necessary 
to elaborate on this concept. 
  In conclusion, our fi  ndings elucidate the role of RUNX 
proteins in iT reg cell development and function. The induc-
tion of the transcription factors RUNX1 and RUNX3 by 
TGF-      and the subsequent up-regulation of Foxp3 play a 
role in iT reg cell generation and its suppressive capacity. 
  MATERIALS AND METHODS 
  Mice.       Cbfb  F/F   CD4-cre   and Foxp3  GFP   mice have previously been described 
(  Bettelli et al., 2006  ;   Naoe et al., 2007  ).   Cd45.1   and   Rag2      /        mice were 
purchased from Jackson ImmunoResearch Laboratories and Taconic, re-
spectively. For the in vivo Foxp3 conversion assay, naive CD4  +   T cells from 
  Cbfb CD4-cre   or control mice (harboring a   Foxp3-IRES-GFP   allele) were 
adoptively transferred into Rag-defi  cient mice. 5 × 10  6   cells were used per 
transfer. 6 wk later, TCR       +  CD4  +   gated cells from the spleen, mesenteric 
lymph node (MLN), and lamina propria of the small intestine were analyzed 
for Foxp3-GFP expression. All analyses and experiments were performed on 
animals at 6–8 wk of age. Animals were housed under specifi  c pathogen–free 
conditions at the animal facility of the Skirball Institute, and experiments 
were performed in accordance with approved protocols for the New York 
University Institutional Animal Care and Usage Committee. 
Runx proteins also play an essential role during T lympho-
cyte diff  erentiation in the thymus (  Taniuchi et al., 2002  ). 
Runx1 regulates the transitions of developing thymocytes 
from the CD4         CD8         double-negative stage to the CD4  +   
CD8  +   double-positive stage and from the DP stage to the 
mature single-positive stage (  Egawa et al., 2007  ). Runx1 
and Runx3 defi  ciencies caused marked reductions in ma-
ture thymocytes and T cells of the CD4  +   helper and CD8  +   
cytotoxic T cell lineages. In addition, inactivation of both 
Runx1 and Runx3 at the double-positive stages resulted in 
a severe blockage in the development of CD8  +   mature thy-
mocytes. These results indicate that Runx proteins have 
important roles at multiple stages of T cell development and 
in the homeostasis of mature T cells, and suggest that they 
may play a role in nT reg cell development, which remains 
to be elucidated. Furthermore, it was shown that Runx1 
activates   IL-2   and   IFN-       gene expression in conventional 
CD4  +   T cells by binding to their respective promoter. 
RUNX1 interacts physically with Foxp3 protein, and it 
was demonstrated that this interaction might be responsi-
ble for the suppression of IL-2 and IFN-      production and 
up-regulation of T reg cell–associated molecules (  Ono 
et al., 2007  ). 
  It has been shown that Foxp3 also infl  uences Th17 dif-
ferentiation. Specifi   cally, Foxp3 physically interacts with 
ROR     t, and this interaction inhibits ROR    t function ( Zhou 
et al., 2008  ). This relationship of ROR     t and Foxp3 and 
probably yet unknown mechanisms might be the basis of the 
observation that the diff  erentiation of Th17 cells and T reg 
cells is often reciprocal (  Bettelli et al., 2006  ). Recently, data 
suggests that Runx1 may also be involved in regulating   Il17   
transcription, functioning in complex with ROR     t to acti-
vate transcription (  Zhang et al., 2008  ). 
  The Runx3-defi  cient mice develop spontaneous Th2-
dominated autoimmune colitis and asthma (  Brenner et al., 
2004  ;   Fainaru et al., 2005  ).   Cbfb  f/f   Cd4   mice also show a 
spontaneous Th2 dominated disease, with increased serum 
IgA, IgG1, and IgE titers and lymphocyte and eosinophil in-
fi  ltration of the lung (  Naoe et al., 2007  ). All these phenotypes 
were previously attributed to a loss of Th2 silencing whereas 
our fi  ndings additionally suggest that loss of T reg function 
plays a role. We have shown a link between Foxp3 induction 
in iT reg cells and RUNX1 and RUNX3. RUNX proteins 
play a central role in pathways regulating cell growth and dif-
ferentiation, and their interaction with the TGF-      pathway 
is of particular interest. 
naive CD4  + 8        T cells from   Cbfb  F/F  CD4-cre   (left) and control   Cbfb  F/+  CD4-cre   mice  ( Cd45.2  ; right ) were activated in vitro with anti-CD3/28 mAb, 50 U/ml 
IL-2, and 2.5 ng/ml TGF-     . After 3 d, Foxp3-GFP  +   cells were FACS-sorted and mixed with CFSE-loaded naive CD45.1  +   CD4 +   cells at the indicated ratios. 
These were then incubated with inactivated splenocytes and anti-CD3 mAb. After a further 4 d, CD45.1  +   cells were analyzed for CFSE dilution. (C) As a 
control,   Cbfb  F/+  CD4-cre   CD4 +   T cells activated in absence of TGF-      were mixed with CFSE-loaded naive CD45.1  +   CD4 +   cells at the indicated ratios. Four 
days later CD45.1  +   cells were analyzed for CFSE dilution. The median division number (of the naive CD45.1  +   CD4 +   cells in the cultures containing Foxp3-
GFP  +   cells) is indicated in each of the histograms. One of three experiments is shown. (D) Human naive CD4  +   T cells, transfected with RUNX1 and RUNX3 
siRNA and cultured under iT reg differentiating conditions were used in an in vitro suppression assay, cultured together with autologous CFSE-labeled 
CD4  +   T cells, and stimulated with anti-CD3 mAb. The CFSE dilution of the CD4  +   T cell responder cells was analyzed after 5 d by fl  ow cytometry. The T reg/
responder CD4  +   T cell ratios used were 1:20, 1:10, and 1:5. One of two experiments is shown.     
 2712 RUNX1 and RUNX3 in functional inducible T regulatory cells   | Klunker et al. 
10  5   APCs + 1 μg/ml anti-CD3 mAb per well of a 96 well round bottom 
plate. Proliferation of the eff  ector cells was analyzed by CFSE dilution. 
Apoptosis of the cells was investigated by annexin V staining and fl  ow cy-
tometry. Positive and negative control gates were made according to T cells 
cultured only in the presence of IL-2 without anti-CD3/28 stimulation. 
  Human naive CD4  +   T cells were isolated by negative selection by 
MACS from PBMCs and either transfected with a scrambled siRNA or with 
a combination of RUNX1 and RUNX3 siRNA. Cells were then cultured 
under iT reg cell diff  erentiating conditions and mixed with 2 × 10  5   autolo-
gous irradiated PBMCs that were used as APCs and autologous CFSE-
labeled CD4  +   T cells. T reg cell to responder cell ratio was 1:20, 1:10, and 
1:5. To check the proliferation of the CD4  +   T cells without suppression, no 
T reg cells were added in a control group. Cells were stimulated with 2.5 μg/ml 
anti-CD3 mAb, cultured in a 96-well plate and the proliferation of the 
eff  ector cells was determined by analyzing the CFSE dilution by fl  ow cy-
tometry after 5 d of culture. Gating on the CD4  +  CFSE  +   T cells enabled the 
exclusion of APCs and T reg cells. 
  Cloning of the   FOXP3   promoter, construction of mutant   FOXP3   
promoter, and RUNX expression plasmids.     The   FOXP3   promoter 
was cloned into the pGL3 basic vector (Promega Biotech) to generate pGL3 
FOXP3 -511/+176 (  Mantel et al., 2006  ). Site-directed mutagenesis for the 
three putative RUNX binding sites in the   FOXP3   promoter region was 
introduced using the QuickChange kit (Stratagene), according to the man-
ufacturer’s instructions and confi  rmed by sequencing the DNA. The follow-
ing primers and their complementary strands were used: foxp runx-333, 
forward 5     -CACTTTTGTTTTAAAAACTGTCCTTTCTCATGAG  CCC-
TATTATC-3     ; foxp runx-333 reverse 5     -GATAATAGGGCTCATGA-
GAAAGGACAGTTTTTAAAACAAAAGTG-3     ; foxp runx-287 forward 
5     -CCTCTCACCTCTGTCCTGAGGGGAAGAAATC-3     ; foxp runx-287 
reverse 5     -GATTTCTTCCCCTCAGGACAGAGGTGAGAGG-3     ; foxp 
runx-53 forward 5     -GCTTCCACACCGTACAGCGTCCTTTT  TCTT-
CTCGGTATAAAAG-3     ; foxp runx-53 reverse 5     -CT  T  TTATACCG-
AGAAGAAAAAGGACGCTGTACGGTGTGGAAGC-3     . 
  The human   RUNX1   fragment from the Addgene plasmid 12504 (  Biggs 
et al., 2006  ) pFlagCMV2-AML1B was sub-cloned in the pEGFPN1 vector 
(Clontech Laboratories). The   RUNX3   vector pCMV human RUNX3, 
which was a gift from K. Ito (Institute of Molecular and Cell Biology, Pro-
teos, Singapore) was subcloned into pEGFPN1 vector (Clontech Laborato-
ries;   Yamamura et al., 2006  ). 
  Transfections and reporter gene assays.     T cells were rested in serum-free 
AIM-V medium overnight. 3.5 μg of the   FOXP3   promoter luciferase reporter 
vector or a combination together with the   RUNX1  ,   RUNX3   pEGFPN1 vector, 
and 0.5 μg phRL-TK were added to 3 × 10  6   CD4  +   T cells resuspended in 
100 μl of Nucleofector solution (Lonza) and electroporated using the program 
U-15. After a 24-h culture in serum-free conditions and stimuli as indicated in 
the fi  gures, luciferase activity was measured by the dual luciferase assay system 
(Promega) according to the manufacturer’s instructions. PMA/ionomycin was 
used to stimulate the cells, because the transfection was only transient and the lu-
ciferase assay required a strong and fast stimulation of the cells. To evaluate the 
eff  ect of overexpression of RUNX1 or RUNX3 on FOXP3 protein levels, 
CD4  +   T cells were preactivated with 2 μg/ml phytohemagglutinin (Sigma-
Aldrich) in serum-free AIM-V medium in the presence of 1 nmol/liter IL-2 
(Roche) for 12 h, and then transfected with the vector pEGFPN1 containing the 
  RUNX1   or   RUNX3   fragment using the Nucleofector system (Amaxa Biosys-
tems) and the program T-23. FOXP3 expression was evaluated by fl  ow cytom-
etry after 48 h of culture in AIM-V medium containing 1 nmol/liter IL-2. 
  RNA interference.     CD4  +   or naive CD4  +   T cells were resuspended in 100 μl 
of Nucleofector solution (Lonza) and electroporated with 2 μM siRNA 
using the Nucleofector technology program U-14 (Lonza). Five diff  erent 
Silencer or Silencer Select Pre-designed siRNAs for RUNX1 (Applied Bio-
systems) and three Silencer Pre-designed siRNAs for RUNX3 (Applied 
Biosystems) were tested, and the best was selected for all further experiments. 
  Isolation of PBMCs, CD4  +   T cells, and culture conditions.     Human 
PBMCs were isolated by Ficoll (Biochrom) density gradient centrifugation 
and CD4+ T cells were then isolated using the Dynal CD4  +   Isolation kit 
(Invitrogen) according to the manufacturer’s instructions. The purity of 
CD4  +   T cells was initially tested by fl  ow cytometry and was ≥95%. Cells 
were stimulated with the following combination of mAbs to T cell surface 
molecules (  Meiler et al., 2008  ): anti-CD2 (clone 4B2 and 6G4; 0.5 μg/ml), 
anti-CD3 (clone OKT3; 0.5 μg/ml), and anti-CD28 mAb (clone B7G5; 
0.5 μg/ml; all from Sanquin) and cultured in serum-free AIM-V medium 
(Life Technologies) with the addition of 1 nmol/liter IL-2 (Roche). TGF-      
(R&D Systems) was used at 5 ng/ml, if not stated otherwise. A combination 
of PMA (25 ng/ml) and ionomycin (1 mg/ml; Sigma-Aldrich) was used. 
  Human CD4  +   CD127         CD25  high   and CD4  +   CD127  +   CD25  neg   cells were 
purifi  ed by fl  ow cytometry using anti-CD127, anti–CD25-PC5 (Beckman 
Coulter), and anti–CD4-FITC antibodies (Dako). 
  Mouse naive (CD62L  hi  44  lo  25        ) CD4  +   T cells were purifi  ed by fl  ow cy-
tometry and activated in vitro with 5 μg/ml plate-bound anti-CD3 and 
1 μg/ml soluble anti-CD28 antibodies (eBioscience) in RPMI supplemented 
with 10% FCS, 5 mM      -mercaptoethanol, and antibiotics. Neutralizing 
anti–IFN-      and anti–IL-4 mAbs (BD) were used at 1 μg/ml concentrations 
when indicated. 
  In vitro T cell diff  erentiation.     CD4  +   CD45RA  +   magnetically sorted 
(CD45RO depletion with AutoMACS; Miltenyi Biotec) cells were stimu-
lated with immobilized plate-bound anti-CD3 (1 μg/ml; OKT3; IgG1) and 
anti-CD28 (2 μg/ml). For Th1 diff  erentiation conditions, cells were stimu-
lated with the following: 40 ng/ml IL-2, 5 μg/ml anti–IL-4, and 25 ng/ml 
IL-12 (R&D Systems). For Th2 conditions, cells were stimulated with the 
following: 40 ng/ml IL-2, 25 ng/ml IL-4, and 5 μg/ml anti–IL-12 (R&D 
Systems). For T reg cell conditions, cells were stimulated with the following: 
40 ng/ml IL-2, 5 ng/ml TGF-     , 5 μg/ml anti–IL-12, 5 μg/ml anti–IL-4. 
For Th17 conditions, cells were stimulated with the following: 40 ng/ml 
IL-2, 20 ng/ml IL-6, 5 ng/ml TGF-     , 20 ng/ml IL-23 (Alexis Biochemicals 
Corp.), 10 ng/ml IL-1     , 5 μg/ml anti-IL-4, and 5 μg/ml anti–IL-12 were 
used. Proliferating cells were expanded in medium containing IL-2. The 
cytokine profi  le of these cells demonstrated that IFN-      is the predominant 
cytokine in Th1 cells, IL-4 and IL-13 in Th2 cells, and IL-17 in Th17 cells 
(  Akdis et al., 2000  ;   Burgler et al., 2009  ). 
  Immunohistochemistry.     Human tonsils were obtained from tonsillectomy 
samples of hypertrophic and obstructive tonsils without a current infection. 
Ethical permission was obtained from Cantonal Ethics Commission, and in-
formed consent was obtained from patients. Paraformaldehyde-fi  xed tonsil 
cryosections were stained with unconjugated rabbit IgG polyclonal antibody 
to human RUNX1 (Santa Cruz Biotechnology, Inc.) or unconjugated mouse 
IgG1 mAb to human RUNX3 (Abcam). After a washing step, the sections 
were stained with the corresponding secondary antibodies. RUNX1-binding 
antibodies were detected by using Alexa Fluor 633–conjugated goat anti–
rabbit IgG and RUNX3-binding antibodies were detected by using Alexa 
Fluor 532–conjugated goat anti–mouse IgG1. Afterward, the sections were 
washed and in the case of RUNX3 staining a blocking step with an unconju-
gated mouse IgG1 mAb was used. Finally, the sections were stained with 
Alexa Fluor 488–conjugated mouse IgG1 mAb to human FOXP3 (eBiosci-
ence) or the corresponding isotype control. Tissue sections were stained with 
DAPI for the demonstration of nuclei and mounted with Prolong antifade 
(Invitrogen). Images were acquired and analyzed using the confocal micro-
scope DMI 4000B and the TCS SPE system (both from Leica). 
  In vitro suppression assays.     Mouse Foxp3  +   CD4  +   CD8         T cells were 
FACS purifi  ed based on GFP expressed from a Foxp3-IRES-GFP knock-in 
allele (  Foxp3  GFP    ). Naive (CD62L  hi  44  lo  25        ) CD4  +   T cells (eff  ectors) were 
FACS-purifi  ed from   Cd45.1   mice, then loaded with 5 μM CFSE (Invitro-
gen). Total splenocytes from C57BL/6 mice inactivated with 50 μg/ml 
mitomycin C (Sigma-Aldrich) for 45 min were used as APCs. A total of 
4 × 10  5   CD4  +   cells (CFSE-loaded CD25         plus Foxp3-GFP  +  ) was mixed with JEM VOL. 206, November 23, 2009 
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HRP-labeled mAb (Cell Signaling Technology) and visualized with a LAS-
1000 gel documentation system (Fujifi  lm). To confi  rm sample loading and 
transfer membranes were incubated in stripping buff  er and reblocked for 1 h 
and reprobed using anti-GAPDH (6C5; Ambion) and developed using an 
anti–mouse IgG HRP-labeled mAb (Cell Signaling Technology). 
  Pull-down assay.     HEK293T cells were transfected with RUNX1 or 
RUNX3 using the Lipofectamine 2000 reagent (Invitrogen) according to 
the manufacturer’s instruction. Cells were lysed by sonication in HKMG 
buff  er (10 mM Hepes, pH 7.9, 100 mM KCl, 5 mM MgCl  2  , 10% glycerol, 
1 mM DTT, 0.5% Nonidet P-40) containing a protease inhibitor cocktail 
(Roche Diagnostics). The cell lysate was precleared using streptavidin-
agarose beads (GE Healthcare), incubated with biotinylated double-stranded 
oligonucleotides containing the wild-type or mutated RUNX binding sites, 
and polydeoxyinosinicdeoxycytidylic acid (Sigma-Aldrich). A combination 
of all three oligonucleotides containing the mutated or the wild-type bind-
ing sites was used in the assay. DNA-bound proteins were collected with 
streptavidin-agarose beads, washed with HKMG buff  er, and fi  nally resus-
pended in NuPAGE loading buff  er (Invitrogen Life Technologies), heated 
to 70°C for 10 min, and separated on a NuPAGE 4–12% Bis-Tris gel (Invit-
rogen Life Technologies). The proteins were electroblotted onto a PVDF 
membrane (GE Healthcare) and detected using RUNX1 or RUNX3 anti-
bodies described in the previous section. 
  Promoter enzyme immuno assay.     As performed in the pull-down assay, 
HEK293T cells were transfected with RUNX1 or RUNX3 and subse-
quently lysed. Insoluble material was removed by centrifugation. 384-well 
plates, precoated with streptavidin (Thermo Fisher Scientifi  c) were washed 
3 times with washing buff   er (PBS and 0.05% Tween 20). Biotinylated 
  FOXP3   promoter/oligonucleotides probes containing the RUNX binding 
sites were added (1 pmol per well; 50 fmol/μl) and incubated for 1 h at room 
temperature. Either a combination of all three oligonucleotides containing 
the mutated or the wild-type binding sites was used or single oligonucle-
otides were used in the assay. After 3 washing steps with washing buff  er, the 
nuclear extract was added (concentration > 0.2 μg/μl) and incubated over-
night at 4°C. The lysates were incubated with 10 μg of poly-deoxyinosinic-
deoxycytidylic acid (Sigma-Aldrich). The plate was washed with HKMG 
buff  er and incubated with a 1:1000 dilution of rabbit anti-RUNX1 (ab11903, 
Abcam) or 1:200 dilution of rabbit anti-RUNX3 (H-50, Santa Cruz Bio-
technology, Inc.) at 4°C for 2 h. After three washing steps with HKMG 
buff  er, a secondary antibody (anti–rabbit IgG-HRP, 1:3,000 in HKMG buf-
fer, Cell Signaling Technology) was added, and the plate was incubated for 
1 h at 4°C. The wells were washed 4 times with HKMG buff  er before add-
ing the substrate reagent (R&D Systems). The colorimetric reaction was 
stopped by adding 2 M H  2  SO  4  . Absorbance at 450 nm was measured using 
a microplate reader (Berthold Technologies). 
  ChIP.     Human naive CD4  +   T cells were cultured either with IL-2 only or 
with IL-2, anti-CD2/3/28, and TGF-      for 72 h, and protein–DNA com-
plexes were fi  xed by cross-linking with formaldehyde in a fi  nal concentra-
tion of 1.42% for 15 min. Formaldehyde was quenched with 125 mM 
glycine for 5 min, and cells were subsequently harvested. The ChIP assay 
was performed as described in the fast chromatin immunoprecipitation 
method (  Nelson et al., 2006  ). Cells were lysed with immunoprecipitation 
buff  er (150 mM NaCl, 50 mM Tris-HCl, pH 7.5, 5 mM EDTA, NP-40 
[0.5% vol/vol]) containing phosphatase (Roche) and protease inhibitors 
cocktails (Roche), the nuclear pellet was washed, the chromatin was sheared 
by sonication and incubated with antibodies for RUNX1 (H-65 X; Santa 
Cruz Biotechnology, Inc.), RUNX3 (H-50 X; Santa Cruz Biotechnology, 
Inc.), CBF      (PEBP2     ; FL-182 X; Santa Cruz Biotechnology, Inc.), and as 
controls normal rabbit IgG (Santa Cruz Biotechnology, Inc.), anti-human 
RNA polymerase II antibody, and mouse control IgG (both from SA Bio-
sciences). The cleared chromatin was incubated with protein A agarose 
beads and, after several washing steps, DNA was isolated with 10% (wt/vol) 
Chelex 100 resin. Samples were treated with proteinase K at 55°C for 
The Silencer Negative Control #1 siRNA (Applied Biosystems) was used 
for normalization. Cells were then left unstimulated or were stimulated after 
12 h with anti-CD2, anti-CD3, and anti-CD28. Cells were cultured in se-
rum-free AIM-V medium with the addition of 1 nmol/l IL-2 (Roche). Cells 
were harvested for mRNA detection of the target genes after 24 h and for 
protein detection after 48 h. 
  RNA isolation and cDNA synthesis.     RNA was isolated using the 
RNeasy Mini kit (QIAGEN) according to the manufacturer’s protocol. Re-
verse transcription of human samples was performed with reverse-transcription 
reagents (Fermentas) with random hexamers according to the manufac-
turer’s protocol. 
  Real-time PCR.     PCR primers and probes were designed based on the se-
quences reported in GenBank with the Primer Express software version 1.2 
(Applied Biosystems) as follows: FOXP3 forward primer, 5     -GAA  ACA  G  C-
ACATTCCCAGAGTTC-3     ; FOXP3 reverse primer, 5     -ATGGCC  CA  G-
CGGATGAG-3     ; EF-1a forward primer, 5     -CTGAACCATCCAGGCC-
AAAT-3     ; and EF-1a reverse primer, 5     -GCCGTGTGGCAATCCAAT-3     , 
as previously described (  Mantel et al., 2007  ). GATA3 forward primer, 
5     -GCGGGCTCTATCACAAAATGA-3     ; and GATA3 reverse primer 
5     -GCTCTCCTGGCTGCAGACAGC-3      (  Mantel et al., 2007  ). T-bet 
forward primer, 5     -GATGCGCCAGGAAGTTTCAT-3     ; T-bet reverse 
primer, 5     -GCACAATCATCTGGGTCACATT-3     ; RORC2 forward 
primer, 5     -CAGTCATGAGAACACAAATTGAAGTG-3     ; and RORC2 
reverse primer 5     -CAGGTGATAACCCCGTAGTGGAT-3     . The pre-
pared cDNAs were amplifi  ed using SYBR green PCR master mix (Fermentas) 
according to the recommendations of the manufacturer in an ABI PRISM 
7000 Sequence Detection System (Applied Biosystems). 
  RUNX1 and RUNX3 mRNA was detected by using TaqMan Gene 
Expression Assays from Applied Biosystems and used according to the man-
ufacturer’s instruction using TaqMan master mix using a 7000 real-time 
PCR system (Applied Biosystems). PCR amplifi  cation of the housekeeping 
gene encoding elongation factor (EF)-1      or by using the 18S rRNA Gene 
Expression Assay (Applied Biosystems) was performed to allow normaliza-
tion between samples. Relative quantifi  cation and calculation of the range of 
confi  dence was performed using the comparative           CT method (Applied 
Biosystems). The percentage of FOXP3 mRNA in siRNA-mediated 
RUNX knockdown cells was calculated in relation to cells, which were 
transfected with scrambled control siRNA. Arbitrary units show the 2       (     ct)   
values multiplied by 10,000 incorporating the ct values of the gene of inter-
est and the housekeeping gene. 
  Flow cytometry.     For analysis of human FOXP3 expression on the single-
cell level, cells were fi  rst stained with the monoclonal CD4 mAb (Beckman 
Coulter), and after fi  xation and permeabilization, they were incubated with 
anti–human Foxp3-Alexa Fluor 488 antibody (BioLegend) based on the 
manufacturer’s recommendations and subjected to FACS (EPICS XL-MCL; 
Beckman Coulter). A mouse IgG1 antibody (BioLegend) was used as an iso-
type control. Data were analyzed with the CXP software (Beckman Coulter). 
Cells were cultured with IL-2, and then left unstimulated or stimulated with 
anti-CD2/-CD3/-CD28 mAb. 
  Flow cytometry analyses of the mouse cells were performed on an 
LSRII (BD) and cell sorting was performed on a FACSAria (BD). All anti-
bodies for these experiments were purchased from eBioscience or BD. 
  Western blotting.     For human RUNX1 and RUNX3 analysis on the pro-
tein level, 10  6   cells were lysed and loaded next to a protein-mass ladder (In-
vitrogen) on a NuPAGE 4–12% Bis-Tris gel (Invitrogen). The proteins were 
electroblotted onto a PVDF membrane (GE Healthcare). Unspecifi  c binding 
was blocked with 3% milk in TBS Tween, and the membranes were subse-
quently incubated with a 1:1,000 dilution of rabbit anti-RUNX1 (ab11903; 
Abcam) or 1:200 dilution of rabbit anti-RUNX3 (H-50; Santa Cruz Bio-
technology, Inc.) in blocking buff  er containing 3% milk in TBS Tween 
overnight at 4°C. The blots were developed using an anti-rabbit IgG 2714 RUNX1 and RUNX3 in functional inducible T regulatory cells   | Klunker et al. 
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30 min. The proteinase K was then inactivated by boiling the samples for 
10 min. The purifi  ed DNA was used in a real-time PCR reaction. Specifi  c 
primers for the FOXP3 promoter, spanning the region from      87 to      3, 
FOXP3 promoter forward primer 5     -AGAGGTCTGCGGCTTCCA-3     , 
FOXP3 promoter reverse primer 5    -GGAAACTGTCACGTATCAAAAA-
CAA-3     , or control GAPDH primer (SA Biosciences) for the RNA poly-
merase II were used. A negative control PCR for each immunoprecipitation 
using IGX1A negative control primer targeting ORF-free intergenic DNA 
(SA Biosciences) was used. The fold enrichment in site occupancy was cal-
culated incorporating IgG control values and input DNA values using the 
ChampionChIP qPCR data analysis fi  le (SA Biosciences). 
  Quantifi  cation of cytokine levels.     IL-4, IL-5, IL-6, IL-10, IL-13, IL-17, 
and IFN-      secretion was assessed using fl  uorescent bead-based technology. 
The Bio-Plex-hu Cytokine Panel, 17-Plex Group 1 was used according 
to the manufacturer’s instructions (Bio-Rad Laboratories). Fluorescent sig-
nals were read and analyzed using the Bio-Plex 200 System (Bio-Rad 
Laboratories). 
  Online supplemental material.     Fig. S1 shows the induction of 
RUNX1, RUNX3, and FOXP3 mRNA in human CD4  +   T cells after 
anti-CD2/3/28 mAb and TGF-      stimulation. Fig. S2 shows decreased 
RUNX1 and RUNX3 mRNA and protein expression after siRNA-medi-
ated knockdown and decreased FOXP3 expression in human CD4  +   T cells 
after RUNX1 and RUNX3 knockdown. Fig. S3 shows the quantifi  cation 
of IL-4, IL-5, IL-10, IL-13, and IFN-      levels in control siRNA transfected 
or RUNX1 and RUNX3 siRNA transfected human CD4  +   T cells. Fig. S4 
shows the putative RUNX binding sites in the   FOXP3   core promoter se-
quence of human, mouse, and rat. Fig. S5 shows the induction of FOXP3 
protein after overexpression of RUNX1 and RUNX3 in human CD4+ T 
cells. Fig. S6 shows that endogenous IL-4 and IFN-      do not eff  ect Foxp3 
expression in naive CD4  +   T cells of   Cbfb  F/F   CD4-cre   and   Cbfb  F/F     control 
mice, which were stimulated with anti-CD3 and anti-CD28 mAbs, IL-2 
and TGF-      in the absence or presence of anti-IL-4 and anti-IFN-      neu-
tralizing mAbs. Fig. S7 shows similar cell death (A) and proliferation (B) 
of Foxp3  +   and Foxp3         cells in   Cbfb  F/F   CD4-cre   and   Cbfb  F/F     control mice 
cultures. Online supplemental material is available at http://www.jem
.org/cgi/content/full/jem.20090596/DC1. 
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